Evidence map›Paper›PMID 41726712›Full record

ArticleACS omega2026

Repositioning HDAC Inhibitors for Glioma Treatment: Synthesis and Biological Evaluation.

Luciana Costa Furtado, Karoline de Barros Waitman, Nuno A T F Silva, Leticia Marcelino Gouvea, Thales Kronenberger, Mônica Franco Zannini Junqueira Toledo, Elthon Gois Ferreira, João Agostinho Machado-Neto, Frank A E Kruyt, Roberto Parise Filho and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Luciana Costa FurtadoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Avenida Professor Lineu Prestes 1524, 05508-000 São Paulo, Brazil.ORCID https://orcid.org/0000-0002-2306-7959
Karoline de Barros WaitmanDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, Avenida Professor Lineu Prestes, 580, 05508-000 São Paulo, Brazil.
Nuno A T F SilvaDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, Avenida Professor Lineu Prestes, 580, 05508-000 São Paulo, Brazil.
Leticia Marcelino GouveaDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Avenida Professor Lineu Prestes 1524, 05508-000 São Paulo, Brazil.
Thales KronenbergerInterfaculty Institute of Microbiology and Infection Medicine (IMIT), University of Tübingen, 72076 Tübingen, Germany.ORCID https://orcid.org/0000-0001-6933-7590
Mônica Franco Zannini Junqueira ToledoDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, Avenida Professor Lineu Prestes, 580, 05508-000 São Paulo, Brazil.ORCID https://orcid.org/0000-0001-7974-4480
Elthon Gois FerreiraDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Avenida Professor Lineu Prestes 1524, 05508-000 São Paulo, Brazil.ORCID https://orcid.org/0000-0001-8381-7849
João Agostinho Machado-NetoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Avenida Professor Lineu Prestes 1524, 05508-000 São Paulo, Brazil.ORCID https://orcid.org/0000-0002-2937-8109
Frank A E KruytDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, DA11, Postbus 30.001, 9700 RB Groningen, The Netherlands.
Roberto Parise FilhoDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, Avenida Professor Lineu Prestes, 580, 05508-000 São Paulo, Brazil.ORCID https://orcid.org/0000-0002-9311-7245
Letícia V Costa-LotufoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Avenida Professor Lineu Prestes 1524, 05508-000 São Paulo, Brazil.ORCID https://orcid.org/0000-0003-1861-5153

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are a type of brain tumor associated with poor patient prognosis, with current treatment, surgical resection when feasible, followed by radiotherapy and chemotherapy (Temozolomide), yielding a median survival of approximately 15 months. In light of the urgent need for more effective therapies, histone deacetylases (HDACs) have emerged as promising targets, given their differential expression across tumor types and disease grades. Although HDAC inhibitors are well established in the treatment of hematological malignancies, their potential is now being explored in solid tumors, including glioblastoma (GBM). In this study, hydroxamate-based (

Identifiers

PMID41726712
PMCPMC12917657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.